Please login to the form below

Not currently logged in
Email:
Password:

Q2 results 2012

This page shows the latest Q2 results 2012 news and features for those working in and with pharma, biotech and healthcare.

Lexapro generics hammer Forest Labs' Q3 results

Lexapro generics hammer Forest Labs' Q3 results. Sales down by nearly 40 per cent. ... Forest Laboratories saw sales in the third quarter of 2012 drop almost 40 per cent on the back of generic competition to its Lexapro antidepressant, which lost patent

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics